Impaired immune function: An early marker for cancer cachexia

Oncology Reports

Volumn 22, Issue 6, 2009, Pages 1403-1406

  Faber, Joyce ^a,d   Vos, Arjan P ^a   Kegler, Diane ^a   Argilés, Josep ^b   Laviano, Alessandro ^c   Garssen, Johan ^a,d   Van Helvoort, Ardy ^a  

^a DANONE RESEARCH   (Netherlands)

^b UNIVERSITY OF BARCELONA   (Spain)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cachexia; Cancer; Immune function; Inflammation; Nutrition

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CACHEXIA; CELLULAR IMMUNITY; CONTACT ALLERGY; CONTROLLED STUDY; DISEASE MARKER; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WEIGHT REDUCTION;

ANIMALS; BIOLOGICAL MARKERS; CACHEXIA; CELL LINE, TUMOR; CYTOKINES; IMMUNE SYSTEM; INFLAMMATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; MONOCYTES; NEOPLASMS; RISK FACTORS; TIME FACTORS;

EID: 70449341710     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000581     Document Type: Article

References (20)

1. Ross JA and Fearon KC: Eicosanoid-dependent cancer cachexia and wasting. Curr Opin Clin Nutr Metab Care 5: 241-248, 2002.
2. Van Cutsem E and Arends J: The causes and consequences of cancer-associated malnutrition. Eur J Oncol Nurs 9 (Suppl. 2): S51-S63, 2005.
3. Argiles JM, Alvarez B and Lopez-Soriano FJ: The metabolic basis of cancer cachexia. Med Res Rev 17: 477-498, 1997.
4. Evans C, Dalgleish AG and Kumar D: Review article: immune suppression and colorectal cancer. Aliment Pharmacol Ther 24: 1163-1177, 2006.
5. Hadden JW: Immunodeficiency and cancer: prospects for correction. Int Immunopharmacol 3: 1061-1071, 2003.
6. Young MR: Eicosanoids and the immunology of cancer. Cancer Metastasis Rev 13: 337-348, 1994.
7. Herber DL, Nagaraj S, Djeu JY and Gabrilovich DI: Mechanism and therapeutic reversal of immune suppression in cancer. Cancer Res 67: 5067-5069, 2007.
8. Ben-Baruch A: Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 16: 38-52, 2006.
9. Whiteside TL: Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16: 3-15, 2006.
10. Van Bokhorst-De van der Schueren MA: Nutritional support strategies for malnourished cancer patients. Eur J Oncol Nurs 9 (Suppl. 2): S74-S83, 2005.
11. Nitenberg G and Raynard B: Nutritional support of the cancer patient: issues and dilemmas. Crit Rev Oncol Hematol 34: 137-168, 2000.
12. Muscaritoli M, Costelli P, Aversa Z, Bonetto A, Baccino FM and Rossi Fanelli F: New strategies to overcome cancer cachexia: from molecular mechanisms to the 'Parallel Pathway'. Asia Pac J Clin Nutr 17 (Suppl. 1): S387-S390, 2008.
13. Tanaka Y, Eda H, Tanaka T, et al: Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res 50: 2290-2295, 1990.
14. Strassmann G, Fong M, Kenney JS and Jacob CO: Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89: 1681-1684, 1992.
15. Strassmann G, Jacob CO, Evans R, Beall D and Fong M: Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia. J Immunol 148: 3674-3678, 1992.
16. Tanaka M, Miyazaki H, Takeda Y and Takeo S: Detection of serum cytokine levels in experimental cancer cachexia of colon 26 adenocarcinoma-bearing mice. Cancer Lett 72: 65-70, 1993.
17. Soda K, Kawakami M, Kashii A and Miyata M: Characterization of mice bearing subclones of colon 26 adenocarcinoma disqualifies interleukin-6 as the sole inducer of cachexia. Jpn J Cancer Res 85: 1124-1130, 1994.
18. Sica A and Bronte V: Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117: 1155-1166, 2007.
19. Mantovani A: Cancer: Inflaming metastasis. Nature 457: 36-37, 2009.
20. Bunt SK, Yang L, Sinha P, Clements VK, Leips J and Ostrand-Rosenberg S: Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 67: 10019-10026, 2007.